A B S T R A C T The universal features of the histopathology of fibrotic lung disease are derangement of parenchymal collagen and infiltration of the parenchyma with chronic inflammatory cells. To determine if this cellular reaction might be associated with autoimmunity to a constituent of the alveolar interstitium, peripheral blood lymphocytes were exposed to human type I collagen in vitro and evaluated for the production of migration inhibition factor and cytotoxicity. Data from 18 patients with idiopathic pulmonary fibrosis, 8 patients with pulmonary fibrosis other than idiopathic pulmonary fibrosis, 12 patients with nonfibrotic lung disease, and 9 normals demonstrated that circulating lymphocytes from more than 94% of patients with fibrotic lung disease take part in processes where the recognition of collagen results in migration inhibition factor production and lysis of collagen-coated sheep red blood cells. These collagen-induced cell-mediated phenomena are obviated with human T-lymphocyte antiserum. Collagen-induced migration inhibition factor production and cytotoxicity were found in less than 20%/o of patients with nonfibrotic disease and were not found in normals. Qualitatively, there was no organ (lung, skin) or species (human, rabbit) Send
collagen specificity in these assays, but human lung a2 chains were recognized more often than al(I) chains. Circulating lymphocytes from patients with fibrotic disease are present in a normal T to B ratio. These lymphocytes did not incorporate [3H]thymidine when exposed to collagen but did when exposed to T-cell mitogens. These in vitro observations suggest that circulating T-lymphocytes and lung collagen may be intimately associated in the pathogenesis of human fibrotic lung disease. INTRODUCTION The mechanisms leading to the development of pulmonary fibrosis are generally unknown. Even though a specific agent of lung injury can be identified in many cases, it is not understood how injury to the parenchyma leads to fibrosis, what prevents the reestablishment of normal lung structure, or why the fibrosis often progresses after the etiologic agent is removed (1) .
The universal histologic features of all categories of pulmonary fibrosis are derangement of parenchymal collagen and infiltration with chronic inflammatory cells. As one approach to identifying pathogenic mechanisms common to all fibrotic lung disorders, we have reasoned that since parenchymal collagen appears deranged, immunologically competent cells in these patients might recognize collagen as "foreign." Collagen might then act as an antigen that maintains or causes progressive lung injury. As 
Study population
Patients were chosen from the clinical service of the Pulmonary Branch of the National Heart and Lung Institute. Most are part of a multidisciplinary study of interstitial lung diseases and their detailed clinical, roentgenographic, physiologic, and pathologic findings will be presented elsewhere. The study population was divided into four groups relatively homogeneous with respect to the diagnosis of fibrotic lung disease. Group A-idiopathic pulmonary fibrosis (IPF (2) . The other three patients had acute pneumonia; one also had asthma. None of the patients in this group had physiologic findings usually associated with fibrotic lung disease. However, none underwent lung biopsy so the diagnosis of "no fibrosis" was not absolute.
Controls. Nine normal volunteers (35.0±4.1 yr; six males and three females) with no history or clinical evidence of pulmonary disease were used as controls.
'Abbreviations used in this paper: HTLA, rabbit antihuman T-lymphocyte-specific antiserum; IPF, idiopathic pulmonary fibrosis; MIF, migration inhibition factor; SRBC, sheep erythrocytes; VBS, veronal-buffered saline. 2 All data are presented as means±SEM.
Preparation of protein antigens
Human fetal lung collagen was prepared from 16-wkold fetuses as previously described (3) . The human fetal lung was obtained after therapeutic abortion by curettage under regional anesthesia. The investigators in this study had no knowledge of the patients or involvement in the surgical procedure. After extraction, these collagen preparations were purified by multiple salt precipitations. Each preparation was more than 90%o type I collagen; upon electrophoresis in sodium dodecyl sulfate acrylamide gels, al, a2, ,B, and y components could be identified. This material will be subsequently referred to as "collagen." al(I) and a2 chains were purified from this collagen by carboxymethyl-cellulose chromatography; each al(I) and a2 preparation was more than 95% pure (3).
Skin collagen was isolated from 10-wk-old rabbits fed 0.9%/o ,aminopropionitrile for 4 wk, as previously described (4). This collagen preparation was more than 90% pure and more than 95% type I collagen.
Human skin collagen was a gift of Dr. J. Harper; bovine serum albumin and transferrin were from Sigma Chemical Co., St. Louis, Mo; rabbit serum albumin was from Miles Laboratories, Inc., Elkhart, Ind.; and streptokinase-streptodominase was from Lederle Laboratories, Pearl River, N. Y.
The collagen preparations were dissolved in 1 M NaCl for 12 h at 4°C and centrifuged (1,000 g, 30 min). The supematant was removed, dialyzed against 0.15 M NaCl, sterilized (0.22-pun Swinnex filter, Millipore Corp., Bedford, Mass.) and finally dialyzed against RPMI medium 1640 supplemented with L-glutamine (2 mM), Hepes buffer (25 mM), penicillin (100 U/ml), and streptomycin (100 ,ug/ml) (final pH 7.4; Grand Island Biological Co., Grand Island, N. Y.) (This supplemented RPMI-1640 will be referred to as "medium"). Final collagen concentrations were determined by hydroxyproline analysis (4 A portion (50 1,u) of this mixed suspension of lymphocytes and macrophages was introduced into each capillary tube and centrifuged (100 g, 10 min); the tubes were cut and affixed inside the migration inhibition chamber as described above. Antigen (1-50 ug/ml) in medium (0.5 ml) was introduced into the chamber and after a 24-48-h incubation at 370C, the percent MIF was determined as described for the indirect assay. In both the direct and indirect assays, the area of migration for three controls (no antigen) and three assays with antigen were averaged before calculating the percent of MIF.
Lymphocyte-mediated cytotoxicity and the final pellet was resuspended at 4% (vol/vol) in veronal-buffered saline, pH 7.4 (VBS). Equal volumes of 4% (vollvol) SRBC and a tannic acid (4 ,ug/ml)-VBS solution were mixed and incubated at 230C for 30 min. The SRBC were pelleted (1000 g, 5 min) and were washed three times with VBS. The tanned SRBC were then resuspended at 2% (vol/vol) in VBS. This suspension of cells was coated with collagen by mixing them with an equal volume of collagen (130 ,ug/ml) in VBS and incubating for 30 min at 23°C (7). Control tanned SRBC were coated similarly with rabbit serum diluted 1:150 in VBS. (The undiluted rabbit serum used throughout was previously absorbed with tanned SRBC to remove any anti-SRBC antibody). After incubation, the collagen and serum-coated SRBC were pelleted and washed three times with rabbit serum diluted 1:150, and the final pellet was resuspended at 1% (vol/vol) in diluted rabbit serum.
Freshly tanned and coated SRBC were pelleted and resuspended at 10%o (vol/vol) 
Lymphocyte transformation
The response of lymphocytes to the nonspecific mitogens phytohemagglutinin-P (Difco Laboratories, Detroit, Mich.), concanavalin-A (Calbiochem, San Diego, Calif.), and rabbit anti-human thymocyte globulin were tested in triplicate (6) . 100 ul of lymphocytes in medium (2 x 
Quantitation of T and B lymphocytes in peripheral blood
Lymphocytes were quantitated as T-cells by those forming erythrocyte (E) rosettes and as B-cells by those forming erythrocyte(E)-human 19S anti-Forssman(A)-mouse serum complement(C) rosettes as previously described (6) .
Cytolysis of peripheral blood T-lymphocytes with anti-human T-cell-specific antiserum (HTLA) Rabbit HTLA, previously shown to be highly specific for human T-lymphocytes, was prepared as described (6) . Lymphocytes were incubated with antiserum (100 y1 of antiserum lysed 3 x 107 T-lymphocytes) or normal rabbit y-globulin at 370C for 30 posure to collagen changed from negative to positive on serial testing. No patient had a positive collageninduced MIF production that later reverted to negative. Collagen-induced MIF production assayed by the direct and indirect methods showed no differences attributable to the assay procedure (Table II) (8) .
To further characterize the supernatant from the indirect MIF assay, lymphocytes from one patient with IPF (N.C.) and one control (A.A.) were incubated with human lung collagen, the cells pelleted, and the supernatants separated into three molecular weight fractions (Table III) . In the patient with IPF, the antigen (collagen) was in the void volume (>100,000 daltons) while the MIF activity was in the included volume (<60,000 daltons). This is consistent with the known molecular weights of MIF (9) and human lung collagen (4). In the control, the collagen was still present in the void volume, but there was no MIF activity in any of the fractions tested (Table III) . That MIF activity produced by IPF lymphocytes was contained in a fraction separate from the antigen obviates the possibility that the results of the MIF assay were secondary to a phenomena involving collagen chemotaxis (10) .
Antigenic specificity for MIF production. The human lung collagen used was over 95% pure type I collagen and it was probably in the native, triplehelical form (or higher aggregates) when incubated in vitro in medium at 370C. When this material was further purified into component al(I) and a2 chains, it still induced production of MIF in most patients tested who had pulmonary fibrosis (Table IV) Collagen-induced cell-mediated cytotoxicity. Preliminary experiments demonstrated that a 0.1% (vol/ vol) suspension of collagen-coated SRBC allowed optimum specific release of 5'Cr when the labeled SRBC were incubated with peripheral blood lymphocytes of patients with pulmonary fibrosis. A ratio of lymphocytes to SRBC of 5:1 gave maximum percent net specific release of 51Cr ( Fig. 2) and this ratio was used in all subsequent experiments. Although all control lymphocytes (group D) gave a percent net specific release of 5'Cr from collagen-coated SRBC of less than 2%, all patients in groups A and B who were tested gave a net specific release of greater than 2% (Fig. 3) . When human or rabbit collagen was used as the antigen, equivalent results were found. Identification of the T-lymphocyte as the cell mediating MIF production and cytotoxicity. When lymphocytes from patients in group A or B were pretreated with rabbit anti-human T-lymphocyte specific antiserum and rabbit complement before the MIF assay, there was no collagen-induced MIF production (Table V) . In contrast, pretreatment of lymphocytes from the same patients with medium alone or medium plus normal rabbit rglobulin and rabbit complement did not alter the induction of MIF production. In the studies with HTLA, the antiserum-sensitive cells were removed (by centrifugation with Ficoll-Hypaque) from the remaining lymphocytes before their incubation with collagen. This is important, since the antiserum-sensitive cells could still produce MIF when exposed to collagen. For example, when the lymphocytes of a patient with IPF (A. D., group A) was treated with antiserum and complement and then exposed to collagen (without removal of the antiserum-sensitive cells), MIF was still produced (39.6+4.7 before antiserum, 41.7+3.9 after antiserum). However, if the treatment with antiserum was followed by removal of the antiserum-sensitive cells (by centrifugation with FicollHypaque), no MIF was produced (15.4+5.2). Similar results were obtained with lymphocytes of patient N. C. (group A; 56.9+6.4 before, 46.8-+4.6 after, 14 .9+4.7 after + Ficoll-Hypaque). Thus, whenever the HTLA was used, it was necessary to reisolate the remaining lymphocytes with Ficoll-Hypaque banding before incubation with the antigen.
Pretreatment of lymphocytes with rabbit HTLA and rabbit complement completely alleviated collagen-induced cytotoxicity, while pretreatment with normal rabbit yglobulin and rabbit complement 1228 T. C. Kravis, A. Ahmed, T. E. Brown, J. D. Fulmer, and R. G. Crystal * All MIF assays were done with 25 ,ug/ml of type I human fetal lung collagen.
All cytotoxicity assays were done with an effector cell to target cell ratio of5: 1. Data are presented as percent net specific release of 5'Cr from collagen-coated sheep red blood cells. § NRyG, nonnal rabbit y-globulin.
allowed the collagen-induced cytotoxicity to be present.
As further evidence that the HTLA destroyed Tcells, the population of viable lymphocytes recovered after incubation with antiserum and complement and then reisolated on Ficoll-Hypaque would not respond to phytohemagglutinin-P or concanavalin A (data not shown).
Even though the lymphocytes (before treatment with anti T-lymphocyte antiserum) from patients in groups A and B incorporated [3H]thymidine normally in response to the nonspecific mitogens phytohemagglutinin-P, concanavalin A, and rabbit anti-human thymocyte globulin, they did not incorporate [3H]-thymidine when exposed to collagen in vitro (Fig.  4) . The in vitro response of lymphocytes from patients in groups A and B to the nonspecific mitogens peaked on day 3, as did the normal controls. The response of lymphocytes to collagen was evaluated by culturing cells with various concentrations of collagen for 48, 72, 96, 120, and 144 h. These longer incubation periods still failed to demonstrate significant [3H]thymidine incorporation.
The number of T-lymphocytes in the peripheral blood of patients with pulmonary fibrosis were within the normal range, as were the number of Bcells (Fig. 5) .
DISCUSSION
The data presented here suggest that lymphocytes from patients with fibrotic lung disease are sensitized to type I collagen. In almost every case, exposure of peripheral blood lymphocytes from these patients to this collagen in vitro results in the production of dence limits for normal controls in our laboratory (6) .
as antigenic and the subsequent production of MIF and cytotoxicity.
Collagen as an antigen. This is not the first example of a clinical disorder in which there is in vitro evidence of immune reactivity to collagen, the most abundant protein in the body. Antibodies against collagen have been found in the sera of patients with rheumatoid arthritis, emphysema, and selective IgA deficiency (11) (12) (13) (14) . Anti-collagen antibodies have also been found in the synovial fluid of patients with rheumatoid arthritis and traumatic synovitis (15), and collagen-anticollagen immune complexes have been found in synovial fluid cells of patients with rheumatoid arthritis (16) .
While most clinical examples of immunity to collagen have involved the humoral immune system, animal experiments have demonstrated that under the proper circumstances, immunization with collagen incites not only circulating collagen antibodies (17) (18) (19) (20) (21) , but cell-mediated immunity as well (22) (23) (24) . Although most of these experimental studies capitalized on species differences in collagen antigenicity to invoke an immune response, Senyk and Michaeli have experimentally induced cell-mediated immune phenomena to homologous collagen in the guinea pig (25) .
The human type I collagen was probably in the native, triple-helical state under the conditions of the lymphocyte incubations (although this is difficult to prove, particularly in the cytotoxicity assay). Thus, it is most likely that the triple-helical form of collagen is the antigen to which the lymphocytes respond in these assays. In addition, the studies with purified al(I) and a2 chains suggest that denatured collagen is also recognized as antigenic by the lymphocytes of these patients and that a2 chains probably have more antigenic determinants than do al(I) chains (17, 18, 21) . However, the recognition of collagen by lymphocytes from patients with fibrotic lung disease is not very specific; they do not distinguish between type I collagen of different species (human, rabbit) or different organs (lung, skin). Since prior studies have shown these type I collagens to be very similar (3, 4, (26) (27) (28) (29) , this cross-reactivity is not surprising.
This lack of specificity demands that if these collagen-induced cell-mediated phenomena are important in vivo, they must occur on a local level, since there is no evidence that the typical patient with fibrotic lung disease has pathologic processes elsewhere. Thus, there must be local lung factors promoting the recognition of collagen as antigenic and/or allowing the collagen-activated cell-mediated immune system to respond. Possible mechanisms that would result in collagen-induced immune reactions in lung but not other tissues include: (a) the structure of lung collagen is altered (e.g., denatured, fragmented); (b) lung collagen is normal but is presented to the local cellular immune system in an abnormal way (e.g., alteration of normal collagen-proteoglycan interaction); or (c) lung collagen is unchanged but the local cell-mediated immune system is somehow abnormal (e.g., enhanced immune reactivity, alteration in normal macrophage-lymphocyte interactions (30) , or loss of local T-lymphocyte suppressor function [31] ). However, if the cell-mediated immune system is abnormal, it is not the absolute number or reactivity of T-lymphocytes alone, since in our patients these cells were present in normal amounts, reacted to T-mitogens normally, and did not spontaneously transform. It is also possible that the T-lymphocytes reacting to collagen are a special subset of the lymphocyte population present in patients with pulmonary fibrosis. Interestingly, even though the lymphocytes from patients with fibrotic disease produced lymphokines when exposed to collagen in vitro, collagen did not induce transformation of these cells. Thus, collagen-induced cellmediated immunity in fibrotic lung disease may be another example of the possible separation of lymphocyte transformation and lymphokine production (32) .
These experiments do not suggest that type I collagen is the only antigen that could cause these phenomena in fibrotic lung disease. The normal human lung parenchyma is known to be composed of at least two types of collagen (types I and III) (26) , in addition to smaller amounts of the less well described type IV (basement membrane) collagen (33) . We have not, as yet, examined the antigenicity of types III and IV collagens in these patients. It is also possible that other connective tissue components from the "deranged" interstitium might act as antigens.
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T. C. Kravis, A. Ahmed, T. E. Brown, J. D. Fulmer, and R. G. Crystal Similar phenomena might also be found in other fibrotic processes (e.g., wound healing, fibrosis of other parenchymal organs), in conditions associated with collagen destruction (e.g., postpartum uterus, extensive burns) or in other disorders associated with connective tissue abnormalities (e.g., scleroderma) (34) . The rarity of collagen-induced MIF production in group C suggests that collagen does not usually invoke cell-mediated immune phenomena in nonfibrotic lung disease, but a larger group will have to be examined to validate this finding.
In vivo signtificance of these in vitro assays. Although we used guinea pig peritoneal macrophages as the target cell for human lymphocyte MIF production, there is evidence that the human alveolar macrophage responds to human lymphocyte MIF (35, 36) . Thus, MIF production could be responsible for the large accumulation of macrophages in the lung parenchyma of patients with fibrotic lung disease. Stimulation of these macrophages could result in the secretion of numerous destructive enzymes, including collagenase, an enzyme specific for collagen (37, 38) . There is also evidence that stimulation of lymphocytes could result in macrophage proliferation (39) and that macrophages can ingest collagen-anticollagen immune complexes (40) . Thus, the recognition of collagen as antigenic by cells in the lung parenchyma theoretically could foment numerous macrophage-lymphocyte-collagen interactions important in the continued tissue destruction in this disease.
As in the in vitro lysis of collagen-coated red blood cells, collagen-activated lymphocytes might utilize lung fibroblasts (or any lung collagen-synthesizing cell) as target cells. This is suggested by data demonstrating that: (a) collagen is bound to membranes of fibroblasts (41); (b) human lung fibroblasts synthesize type I collagen (28) ; and (c) antibodies to collagen are cytotoxic to fibroblasts in culture (42) (43) (44) .
In addition to the cell-mediated phenomena investigated in IPF, studies of the lavage fluid from these patients have demonstrated that the epithelial surfaces of the lower respiratory tracts of these patieints have more polymorphonuclear leukocytes and eosiniophils than normal (45) . Probably, a number
of as yet uninvestigated cell-cell interactions are also important in the pathogenesis of fibrotic disease, of which collagen-induced MIF production and cytotoxicity are just two.
It is possible, of course, that the cell-mediated reactivity to collagen found in patients with fibrotic disease is secondary to chron-ic lung injury rather thani being of primary pathogenic importance in causin-g the injury. Even so, these phenomena may be signiificanit in further extendinig the already deranged alveolar interstitiuimi.
